Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CorMedix Inc CRMD

Healthcare
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections... see more

Recent & Breaking News (NDAQ:CRMD)

CorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America Conference

GlobeNewswire April 11, 2024

CorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLC

GlobeNewswire April 8, 2024

CorMedix Inc. to Present at the Needham Annual Healthcare Conference

GlobeNewswire March 27, 2024

CorMedix Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire March 12, 2024

CorMedix Inc. to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 12, 2024

GlobeNewswire March 6, 2024

CorMedix Inc. Announces Commercial and Reimbursement Updates

GlobeNewswire January 30, 2024

CorMedix Inc. Announces Commercial and Operational Updates

GlobeNewswire January 8, 2024

CorMedix Inc. Announces Appointment of Chief Legal Officer

GlobeNewswire December 15, 2023

CorMedix Inc. Announces Partnership With The Leapfrog Group

GlobeNewswire December 4, 2023

CorMedix Inc. Announces FDA Approval of DefenCath® to Reduce the Incidence of Catheter-Related Bloodstream Infections in Adult Hemodialysis Patients

GlobeNewswire November 15, 2023

CorMedix Inc. Reports Third Quarter and Nine Month 2023 Financial Results and Provides Business Update

GlobeNewswire November 14, 2023

CorMedix Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on November 14, 2023

GlobeNewswire November 2, 2023

CorMedix Inc. Announces Abstract Presentation at Upcoming IDWeek Conference

GlobeNewswire October 11, 2023

CorMedix Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference

GlobeNewswire September 26, 2023

CorMedix Inc. Announces Publication of Phase 3 LOCK IT-100 Study Data in the Clinical Journal of The American Society of Nephrology

GlobeNewswire September 8, 2023

CorMedix Inc. to Present at the H.C. Wainwright Annual Global Investment Conference

GlobeNewswire September 6, 2023

CorMedix Inc. Announces Issuance of U.S. Patent Covering Lead Product Defencath

GlobeNewswire August 30, 2023

CorMedix Inc. Reports Second Quarter and Six Month 2023 Financial Results and Provides Business Update

GlobeNewswire August 8, 2023

CorMedix Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 8, 2023

GlobeNewswire July 26, 2023

CorMedix Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire June 28, 2023